{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:48:57Z","timestamp":1785908937105,"version":"3.56.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.berh.2026.102152","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:13:17Z","timestamp":1778497997000},"page":"102152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bridging clinical phenotypes with molecular mechanisms in autoimmune irAEs: An Etiopathogenic framework"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2603-4913","authenticated-orcid":false,"given":"Whitney","family":"Elg-Salsman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.berh.2026.102152_bib1","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/ijc.35347","article-title":"How many people in the US are eligible for and respond to checkpoint inhibitors: an empirical analysis","volume":"156","author":"Haslam","year":"2025","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.berh.2026.102152_bib2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","article-title":"The foundations of immune checkpoint blockade and the ipilimumab approval decennial","volume":"21","author":"Korman","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.berh.2026.102152_bib3","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with Anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharmacol"},{"issue":"Suppl 7","key":"10.1016\/j.berh.2026.102152_bib4","doi-asserted-by":"crossref","first-page":"vii40","DOI":"10.1093\/rheumatology\/kez297","article-title":"Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy","volume":"58","author":"Abdel-Wahab","year":"2019","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.berh.2026.102152_bib5","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2026.102152_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093054","article-title":"Immune checkpoint inhibitor-related myositis: from biology to bedside","volume":"21","author":"Solimando","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.berh.2026.102152_bib7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Investig"},{"issue":"1","key":"10.1016\/j.berh.2026.102152_bib11","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41467-022-29539-3","article-title":"Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.berh.2026.102152_bib8","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41584-018-0074-9","article-title":"Rheumatic immune-related adverse events from cancer immunotherapy","volume":"14","author":"Calabrese","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2026.102152_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0071-8","article-title":"Single-cell RNA sequencing technologies and bioinformatics pipelines","volume":"50","author":"Hwang","year":"2018","journal-title":"Exp Mol Med"},{"issue":"1","key":"10.1016\/j.berh.2026.102152_bib10","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41467-017-02659-x","article-title":"Single-cell RNA-seq of rheumatoid arthritis synovial tissue using low-cost microfluidic instrumentation","volume":"9","author":"Stephenson","year":"2018","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.berh.2026.102152_bib12","article-title":"The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle","volume":"19","author":"Carvajal","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2026.102152_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.943574","article-title":"Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica","volume":"13","author":"Reitsema","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.berh.2026.102152_bib14","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/rheumatology\/keae099","article-title":"Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement","volume":"64","author":"Vermeulen","year":"2025","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.berh.2026.102152_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003260","article-title":"Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study","volume":"9","author":"Reid","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.berh.2026.102152_bib16","doi-asserted-by":"crossref","first-page":"e508","DOI":"10.1016\/S2665-9913(23)00163-7","article-title":"Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the global burden of disease study 2021","volume":"5","author":"Collaborators","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102152_bib17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13075-017-1229-9","article-title":"Synovitis in osteoarthritis: current understanding with therapeutic implications","volume":"19","author":"Mathiessen","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2026.102152_bib18","doi-asserted-by":"crossref","DOI":"10.1177\/2058738418820760","article-title":"Blocking of checkpoint receptor PD-L1 aggravates osteoarthritis in macrophage-dependent manner in the mice model","volume":"33","author":"Liu","year":"2019","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"8","key":"10.1016\/j.berh.2026.102152_bib19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41584-024-01135-3","article-title":"Update on the pathophysiology and treatment of primary Sjogren syndrome","volume":"20","author":"Baldini","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2026.102152_bib20","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"9","key":"10.1016\/j.berh.2026.102152_bib21","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"24","author":"Warner","year":"2019","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.berh.2026.102152_bib22","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/art.41604","article-title":"Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors","volume":"73","author":"Aldrich","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2026.102152_bib23","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune checkpoint inhibitor-associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution","volume":"138","author":"Anquetil","year":"2018","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.berh.2026.102152_bib24","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.berh.2026.102152_bib25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.berh.2026.102152_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102455","article-title":"Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern","volume":"19","author":"Matas-Garcia","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.berh.2026.102152_bib27","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/ard-2022-223792","article-title":"Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis","volume":"82","author":"Pinal-Fernandez","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:19:08Z","timestamp":1785907148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694226000379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1521694226000379"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2026.102152","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bridging clinical phenotypes with molecular mechanisms in autoimmune irAEs: An Etiopathogenic framework","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2026.102152","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102152"}}